CN112798378A - Immunofluorescence dry tablet recovery agent and application thereof - Google Patents
Immunofluorescence dry tablet recovery agent and application thereof Download PDFInfo
- Publication number
- CN112798378A CN112798378A CN202110126830.9A CN202110126830A CN112798378A CN 112798378 A CN112798378 A CN 112798378A CN 202110126830 A CN202110126830 A CN 202110126830A CN 112798378 A CN112798378 A CN 112798378A
- Authority
- CN
- China
- Prior art keywords
- immunofluorescence
- dry
- parts
- application
- slices
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010166 immunofluorescence Methods 0.000 title claims abstract description 44
- 238000011084 recovery Methods 0.000 title claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 30
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 17
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 8
- 238000002791 soaking Methods 0.000 claims abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 11
- 238000003018 immunoassay Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses an immunofluorescence dry tablet recovering agent and application thereof, relating to the fields of immunoassay and biotechnology application, and comprising the following components in parts by weight: 4-6 parts of 5% SDS, 4.5-5.5 parts of 0.5% Tween-20, 995-1005 parts of PBS solution and application of the immunofluorescence dry-plate recovering agent, wherein the application comprises the following steps: a1: washing the tissue slices or cell samples of the dry slices with PBS solution for 5min each time for 1-2 times; a2: dropwise adding or soaking the immunofluorescence dry-sheet restoration agent on the cleaned tissue slices or cell samples, incubating for 20min by using a shaking table, wherein the temperature is room temperature, and the rotating speed of the shaking table is 60-80 rpm; a3: and (3) washing the incubated tissue slices or cell samples with PBS (phosphate buffer solution) for 5min each time, and finishing the recovery of the immunofluorescence dry slices. The invention can recover the immunofluorescence dry film, can increase the fault tolerance rate of the immunofluorescence experiment, saves the number of samples and saves the experiment time.
Description
Technical Field
The invention relates to the fields of immunoassay and biotechnology application, in particular to an immunofluorescence dry tablet restoring agent and application thereof.
Background
Immunofluorescence is often disposable, i.e., observed by fluorescence microscopy or laser confocal immediately after an experiment. However, in the course of immunofluorescence assay, if there is an operational error, for example, tissue slices or cell sample dry slices are caused by long-term incubation without adding a solution, the background of immunofluorescence is increased, and the final assay result is affected. The prior art can only compensate for errors by re-testing with new tissue sections or cell samples, and often there is no excess sample for making mistakes if the test sample is precious, for example, a tissue sample with infrequent disease or a test sample that requires lengthy molding. For immunofluorescence assay conditions, when studies are needed to cause poor specificity of dry tablets or antibodies, a part of an assay sample is often needed to find suitable assay conditions. This results in an increase in the amount of sample required, prolonging the time of the experiment.
Disclosure of Invention
The invention provides an immunofluorescence dry film restoration agent and application thereof, aiming at the problems in the prior art, the immunofluorescence dry film restoration agent can restore an immunofluorescence dry film, can increase the fault tolerance rate of an immunofluorescence experiment, saves the number of samples and saves the experiment time.
The invention is realized by the following technical scheme: an immunofluorescence dry tablet recovery agent comprises the following components in parts by weight: 4-6 parts of 5% SDS, 4.5-5.5 parts of 0.5% Tween-20, 995-1005 parts of PBS solution.
Further, the paint comprises the following components in parts by weight: 4.59 parts of 5% SDS, 5 parts of 0.5% Tween-20, and 1000 parts of PBS solution.
The application of the immunofluorescence dry tablet recovering agent comprises the following steps:
a1: washing the tissue slices or cell samples of the dry slices with PBS solution for 5min each time for 1-2 times;
a2: dropwise adding or soaking the immunofluorescence dry-sheet restoration agent on the cleaned tissue slices or cell samples, incubating for 20min by using a shaking table, wherein the temperature is room temperature, and the rotating speed of the shaking table is 60-80 rpm;
a3: and (3) washing the incubated tissue slices or cell samples with PBS (phosphate buffer solution) for 5min each time, and finishing the recovery of the immunofluorescence dry slices.
The above includes at least the following advantages:
1. the immunofluorescence dry tablet recovery agent and the application thereof can recover a sealed dry tablet, a primary antibody incubated dry tablet and a secondary antibody incubated dry tablet, and have obvious effects;
2. the immunofluorescence dry film restoration agent and the application thereof can restore the immunofluorescence dry film, can increase the fault tolerance rate of an immunofluorescence experiment, save the number of samples and save the experiment time; meanwhile, experimental conditions are required to be explored for some samples, so that the application of the restoring agent can meet the requirements of dry sample pieces; in addition, some antibodies are less specific and enhanced antibody specificity may also be obtained by the use of the rejuvenating agents of the invention.
Drawings
The accompanying drawings, which are included to provide a further understanding of the embodiments of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the principles of the invention. In the drawings:
FIG. 1 is a graph showing the effect of using an immunofluorescence dry plate restoration agent on a dry plate after sample blocking;
FIG. 2 is a graph showing the effect of using an immunofluorescence dry plate restoration agent on a dry plate after a sample primary antibody incubation;
FIG. 3 is a graph showing the effect of using the immunofluorescence dry plate recovering agent on a dry plate after incubation of a sample secondary antibody.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples and accompanying drawings, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not meant to limit the present invention.
Examples
In one embodiment, the immunofluorescence dry tablet restoration agent comprises the following components in parts by weight: 4-6 parts of 5% SDS, 4.5-5.5 parts of 0.5% Tween-20, 995-1005 parts of PBS solution.
In one embodiment, the immunofluorescence dry tablet restoration agent comprises the following components in parts by weight: 4.59 parts of 5% SDS, 5 parts of 0.5% Tween-20, and 1000 parts of PBS solution.
In one embodiment, the immunofluorescence dry tablet restoration agent comprises the following components in parts by weight: 4 parts of 5% SDS, 4.5 parts of 0.5% Tween-20, 995 parts of PBS solution.
In one embodiment, the immunofluorescence dry tablet restoration agent comprises the following components in parts by weight: 6 parts of 5% SDS, 5.5 parts of 0.5% Tween-20, 1005 parts of PBS solution.
In one embodiment, 5% SDS, 0.5% Tween-20, PBS solution was mixed well to obtain immunofluorescence dry plate restoration agent.
In one embodiment, the application of the immunofluorescence dry-film restoration agent comprises the following steps:
a1: washing the tissue slices or cell samples of the dry slices with PBS solution for 5min each time for 1-2 times;
a2: dropwise adding or soaking the immunofluorescence dry-sheet restoration agent on the cleaned tissue slices or cell samples, incubating for 20min by using a shaking table, wherein the temperature is room temperature, and the rotating speed of the shaking table is 60-80 rpm;
a3: and (3) washing the incubated tissue slices or cell samples with PBS (phosphate buffer solution) for 5min each time, and finishing the recovery of the immunofluorescence dry slices.
Examples of the experiments
Immunofluorescence dried film recovery effect experiment:
dividing the blocked sample, the primary antibody incubated sample and the secondary antibody incubated sample into three groups, observing the three groups under a microscope at 200x and 400x respectively, as shown in figure 1 (a), figure 2 (a) and figure 3 (a), and then treating the three groups with the immunofluorescence dry plate recovery agent of the invention, wherein the treatment method is shown in the example, and the treatment process is observed under a microscope at 200x and 400x as shown in figure 1 (b), figure 2 (b) and figure 3 (b), and the characteristics of the treated blocked sample, the primary antibody incubated sample and the secondary antibody incubated sample dry plate recovery process can be observed.
Experiments show that the immunofluorescence dry tablet restoration agent and the application thereof can restore the closed dry tablet, the primary antibody incubated dry tablet and the secondary antibody incubated dry tablet, and the effect is obvious.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (3)
1. An immunofluorescence dry tablet recovery agent is characterized by comprising the following components in parts by weight: 4-6 parts of 5% SDS, 4.5-5.5 parts of 0.5% Tween-20, 995-1005 parts of PBS solution.
2. The immunofluorescence dry-film restoration agent according to claim 1, which is characterized by comprising the following components in parts by weight: 4.59 parts of 5% SDS, 5 parts of 0.5% Tween-20, and 1000 parts of PBS solution.
3. The application of the immunofluorescence dry tablet recovering agent is characterized by comprising the following steps:
a1: washing the tissue slices or cell samples of the dry slices with PBS solution for 5min each time for 1-2 times;
a2: dropping or soaking the immunofluorescence dry plate restoration agent as defined in claim 1 on the washed tissue slices or cell samples, and incubating for 20min by using a shaking table at room temperature and 60-80 rpm;
a3: and (3) washing the incubated tissue slices or cell samples with PBS (phosphate buffer solution) for 5min each time, and finishing the recovery of the immunofluorescence dry slices.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110126830.9A CN112798378B (en) | 2021-01-29 | 2021-01-29 | Immunofluorescence dry tablet recovery agent and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110126830.9A CN112798378B (en) | 2021-01-29 | 2021-01-29 | Immunofluorescence dry tablet recovery agent and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112798378A true CN112798378A (en) | 2021-05-14 |
| CN112798378B CN112798378B (en) | 2023-03-24 |
Family
ID=75812892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110126830.9A Active CN112798378B (en) | 2021-01-29 | 2021-01-29 | Immunofluorescence dry tablet recovery agent and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112798378B (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002567A1 (en) * | 1988-09-02 | 1990-03-22 | The Ohio State University Research Foundation | Virus-derived antigenic composition and its preparation and use |
| US20050196768A1 (en) * | 2001-02-26 | 2005-09-08 | Campbell Robert E. | Monomeric and dimeric fluorescent protein variants and methods for making same |
| CN101966332A (en) * | 2009-09-29 | 2011-02-09 | 中国人民解放军第三军医大学第一附属医院 | Application of gap junction protein and coding gene thereof in preparing medicament for reversing malignant phenotype of cancer stem cell |
| CN103048470A (en) * | 2012-12-20 | 2013-04-17 | 山西医科大学 | Immunofluorescence histochemistry technology |
| CN107153015A (en) * | 2016-03-02 | 2017-09-12 | 中国石油化工股份有限公司 | A kind of drilling tool for being used to gather the gas in soil |
| CN107290188A (en) * | 2017-08-02 | 2017-10-24 | 南京贻润环境科技有限公司 | A kind of SOIL GAS layering harvester and monitoring method |
| CN107574229A (en) * | 2017-10-20 | 2018-01-12 | 四川农业大学 | A kind of probe groups, kit and application for being used to detect oat chromosome |
| CN108572105A (en) * | 2018-04-13 | 2018-09-25 | 山东中医药大学 | A kind of preparation method of brain tissue frozen section |
| CN109298174A (en) * | 2018-09-26 | 2019-02-01 | 姜云瀚 | A kind of multiple-color immunofluorescence labeling method and imaging method |
| WO2020131342A2 (en) * | 2018-12-03 | 2020-06-25 | The Regents Of The University Of California | High/hypervelocity particle capture and analysis method and apparatus |
| CN111811909A (en) * | 2020-07-01 | 2020-10-23 | 北京基谱生物科技有限公司 | Preparation and application of tissue autofluorescence quencher |
| CN111830256A (en) * | 2020-07-01 | 2020-10-27 | 北京基谱生物科技有限公司 | Immunofluorescence multiple staining kit for paraffin section and using method |
| CN111879590A (en) * | 2020-08-13 | 2020-11-03 | 郑州大学第一附属医院 | Method for reproducing paraffin section by immunofluorescence freezing residual tissue of kidney biopsy |
-
2021
- 2021-01-29 CN CN202110126830.9A patent/CN112798378B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002567A1 (en) * | 1988-09-02 | 1990-03-22 | The Ohio State University Research Foundation | Virus-derived antigenic composition and its preparation and use |
| US20050196768A1 (en) * | 2001-02-26 | 2005-09-08 | Campbell Robert E. | Monomeric and dimeric fluorescent protein variants and methods for making same |
| CN101966332A (en) * | 2009-09-29 | 2011-02-09 | 中国人民解放军第三军医大学第一附属医院 | Application of gap junction protein and coding gene thereof in preparing medicament for reversing malignant phenotype of cancer stem cell |
| CN103048470A (en) * | 2012-12-20 | 2013-04-17 | 山西医科大学 | Immunofluorescence histochemistry technology |
| CN107153015A (en) * | 2016-03-02 | 2017-09-12 | 中国石油化工股份有限公司 | A kind of drilling tool for being used to gather the gas in soil |
| CN107290188A (en) * | 2017-08-02 | 2017-10-24 | 南京贻润环境科技有限公司 | A kind of SOIL GAS layering harvester and monitoring method |
| CN107574229A (en) * | 2017-10-20 | 2018-01-12 | 四川农业大学 | A kind of probe groups, kit and application for being used to detect oat chromosome |
| CN108572105A (en) * | 2018-04-13 | 2018-09-25 | 山东中医药大学 | A kind of preparation method of brain tissue frozen section |
| CN109298174A (en) * | 2018-09-26 | 2019-02-01 | 姜云瀚 | A kind of multiple-color immunofluorescence labeling method and imaging method |
| WO2020131342A2 (en) * | 2018-12-03 | 2020-06-25 | The Regents Of The University Of California | High/hypervelocity particle capture and analysis method and apparatus |
| CN111811909A (en) * | 2020-07-01 | 2020-10-23 | 北京基谱生物科技有限公司 | Preparation and application of tissue autofluorescence quencher |
| CN111830256A (en) * | 2020-07-01 | 2020-10-27 | 北京基谱生物科技有限公司 | Immunofluorescence multiple staining kit for paraffin section and using method |
| CN111879590A (en) * | 2020-08-13 | 2020-11-03 | 郑州大学第一附属医院 | Method for reproducing paraffin section by immunofluorescence freezing residual tissue of kidney biopsy |
Non-Patent Citations (2)
| Title |
|---|
| SAI CHEN ET AL: "Alimentary system is directly attacked by SARS-COV-2 and further prevents immune dysregulation caused by COVID-19", 《INTERNATIONAL JOURNAL OF CLINICAL PRACTICE》 * |
| 陈黎等: "墙式浮标氧气吸入器不同倾斜角度引起患者误吸的相关性", 《西部医学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112798378B (en) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pan et al. | Protargol synthesis: an in‐house protocol | |
| van Glabbeek | The linear time—Branching time spectrum II: The semantics of sequential systems with silent moves extended abstract | |
| Sharma et al. | PROTEINURIA AFTER INJECTION OF HUMAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS FACTOR12 | |
| Buesa et al. | Histology without xylene | |
| Spiegelman et al. | Isolation and characterization of nuclear bodies from protoplasts of Bacillus megaterium | |
| Fuente Mora et al. | Differentiation of podocyte and proximal tubule-like cells from a mouse kidney-derived stem cell line | |
| WO1995024498A1 (en) | Deparaffinization compositions and methods for their use | |
| Rogers et al. | A molecular orbital description of the partitioning of aromatic compounds between polar and nonpolar phases | |
| CN112798378B (en) | Immunofluorescence dry tablet recovery agent and application thereof | |
| CN105973681B (en) | A kind of immunohistochemistry operating method | |
| Bongolan et al. | Decellularization of porcine kidney with submicellar concentrations of SDS results in the retention of ECM proteins required for the adhesion and maintenance of human adult renal epithelial cells | |
| Bae et al. | Preparation of human decellularized peripheral nerve allograft using amphoteric detergent and nuclease | |
| Gomes et al. | Comparison of three staining methods to identify eosinophils in formalin‐fixed canine skin | |
| Karstad | Aleutian disease a slowly progressive viral infection of mink | |
| CN112798377B (en) | Fluorescence quenching recovery agent and application thereof | |
| Momtahan et al. | Using hemolysis as a novel method for assessment of cytotoxicity and blood compatibility of decellularized heart tissues | |
| Went et al. | Immunochemical study of the origin of the mitotic apparatus | |
| Han et al. | Adult Mouse Kidney Stem Cells Orchestrate the De Novo Assembly of a Nephron via Sirt2‐Modulated Canonical Wnt/β‐Catenin Signaling | |
| Parker et al. | Cytoplasmic fibrils in mixed lymphocyte cultures | |
| Kovandova et al. | Antibody‐mediated rejection after liver transplantation—relevance of C1q and C3d‐binding antibodies | |
| McGuigan et al. | Staining characteristics of the gastrin cell | |
| WO1991000333A1 (en) | Enzymatic cleaner | |
| CN103983767A (en) | Kit for detecting alpha-1,3Gal antigen and application thereof | |
| Bradbury et al. | Amyloidosis and lymphoid aplasia in mouse radiation chimaeras | |
| Inagaki et al. | ATP-dependent Cl− uptake by plasma membrane vesicles from the rat brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |